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Mesenchymal  stromal  cells (MSC)  have  been  exploited  for their  immunomodulatory  properties  in the
treatment  of a number  of immune-based  disorders,  including  Graft  versus  Host  Disease  (GvHD)  and
type  1  diabetes.  The  mechanisms  for inducing  therapeutic  effect  still  remain  largely  unknown  however,
with  research  focused  on  understanding  how  MSCs  interact  with  individual  immune  cell  subsets.  Withinvailable online 15 May  2015
eywords:
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nﬂammation
this  review  we  address  what  is  known  about  the interactions  of  MSCs  with  cells  of the  innate  immune
system,  how  they  respond  to  their  microenvironment  and  how  this  relates  to therapeutic  effects  we  see
both  within  in  vivo animal  models  and in clinical  trials.
©  2015  The  Authors.  Published  by Elsevier  B.V.  on  behalf  of European  Federation  of  Immunological
Societies.  This  is  an  open  access  article  under  the CC  BY-NC-ND  licensemmunomodulation
. Introduction
In contrast to the adaptive immune response, the innate sys-
em is non-speciﬁc and fast acting, with responses encoded within
he germline DNA. Triggering is often by recognition of micro-
ial pathogen associated molecular patterns (PAMPS) such as
ipopolysaccharide (LPS), double stranded viral RNA (dsRNA) or
rokaryotic DNA motifs such as CpG. PAMPS directly interact with
oll-like ligand receptors (TLRs) expressed on both parenchyma
nd leukocytes, triggering a cascade of chemokines and cytokines
nvolved in initiation of the inﬂammatory response and leuko-
yte migration [1]. The expression of TLRs on the cell surface of
esenchymal stromal cells (MSCs) suggests their inherent role in
odulating this early immune response [2].
Mechanical tissue barriers, such as the skin and mucous mem-
ranes, provide the ﬁrst line of defense in innate immunity. Many
on-myeloid cells contribute to this defense strategy, including
broblasts and epithelial cells, producing immunomodulatory and
ntimicrobial factors, in addition to their physical barrier func-
ion. Given the location of MSCs within epithelial niches close
o the vessel walls and their phenotypic plasticity, it has been
∗ Corresponding author at: Hematology and Regenerative Medicine (HERM),
ovum 4th ﬂoor, Karolinska University Hospital Huddinge, SE-14186 Stockholm,
weden. Tel.: +46 8 5858 1361; fax: +46 8 746 6699.
E-mail address: Katarina.Leblanc@ki.se (K. Le Blanc).
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165-2478/© 2015 The Authors. Published by Elsevier B.V. on behalf of European Federatio
icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).(http://creativecommons.org/licenses/by-nc-nd/4.0/).
hypothesized that MSCs may  orchestrate epithelial immune
responses by surveilling the local milieu [3].
MSCs have been reported to exhibit immunomodulatory effects
on both humoral and cellular components of the innate immune
system. This review has focused on key cellular interactions and
the potential role of complement in homing of MSCs to the site of
injury.
1.1. MSCs and the complement system
The complement system is a central component of innate immu-
nity and has been implicated in the rejection of transplanted
allografts [4] and more recently linked to the rapid clearance of
systemically circulating MSCs after infusion [5]. Triggering of the
complement cascade can occur via three separate pathways (clas-
sical, lectin or alternative). Activation of the complement cascade
provides chemotactic factors and enhancement of the inﬂam-
matory response, resulting in the recruitment and activation of
leukocytes, enhanced phagocytosis and the formation of mem-
brane attack complexes (MAC), which directly injure the target
cells. Irrespective of the triggering pathway, the central step in
complement activation is the cleavage of C3 into C3a and C3b
[6]. C3b subsequently undergoes further cleavage into the surface-
bound fragments iC3b and C3dg. These fragments, once cell bound,
become ligands for various immune cells expressing the comple-
ment receptors CR1-4 [7].
The complement components C3 and C5 are cleaved by spe-
ciﬁc convertases to the anaphylatoxins C3a and C5a, both of which
n of Immunological Societies. This is an open access article under the CC BY-NC-ND
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re found extensively within inﬂamed and injured tissues. Bone
arrow MSCs (BMMSCs) express the receptors for these anaphyla-
oxins (C3aR and C5aR), suggesting that these breakdown products
re chemotactic agents for the MSCs, promoting their migration
owards the site of inﬂammation. Binding of C3a and C5a to their
eceptors on the cell surface of MSCs enhances MSC  resistance
o oxidative stress and prolongs the activation of intracellular
ignaling pathways involved in MSC  proliferation and protection
rom apoptosis [8]. Binding of C3 to MSCs has also been corre-
ated with a higher degree of suppression of peripheral blood
ononuclear cell proliferation [9]. Cell surface expression of the
omplement inhibitors CD46, CD55 and most predominantly CD59,
llows MSCs to partially inhibit activation of the complement
ystem [10] and protect the MSCs from the lytic activity of com-
lement components [8]. However, this mechanism of defense can
e ineffective in a complement-activated environment and MSCs
re vulnerable to MAC  formation [5].
MSCs additionally secrete the complement inhibitor, factor H
10]. Factor H inhibits complement activation by limiting the activ-
ty of C3 and C5 convertases as well as acting as a co-factor for
actor I in the inactivation of C3b and C4b. MSC  production of
actor H is constitutive, but further up-regulated by exposure to
ro-inﬂammatory cytokines such as interferon- (IFN) and tumor
ecrosis factor  (TNF), but not interleukin (IL)-6 [10].
MSCs themselves are able to trigger the complement cascade via
ll three complement pathways by secreting both C3 and C5 when
xposed to ABO compatible blood and serum [5,8]. It is noted that
he alternative pathway appears to play a major role in MSC  induced
omplement activation [5]. As discussed previously, the rapid clear-
nce of MSCs after systemic infusion, suggests triggering of the
nstant-blood-mediated-inﬂammatory-response (IBMIR) [9]. This
ay  promote the activation and interaction of MSCs with immune
ells within the blood, potentially initiating a cascade of intrinsic
mmunosuppressive functions within both the MSCs and immune
ells i.e. regulatory T-cell (Treg) and M2  macrophage induction to
enerate a sophisticated immunosuppressive environment.
.2. MSCs respond to their cellular microenvironment
The cellular microenvironment and inﬂammatory milieu play
ey roles in determining MSC  phenotype and their effects on the
mmune system [11]. MSCs demonstrate marked plasticity, exert-
ng both pro- and anti-inﬂammatory phenotypes dependent on
hese environmental stimuli [2,12]. Through balancing this acti-
ating or suppressive phenotype MSCs may  be central to regulating
mmune control and tissue repair and regeneration.
MSCs with a predominantly pro-inﬂammatory signature are
ssociated with early stage infection and inﬂammation. Induced by
xposure to TLR2 (peptidoglycan) [13] or TLR4 (LPS) [2] activation,
hey migrate to the site of injury and promote immune induc-
ion [2]. This process is associated with the secretion of chemokine
C-X-C motif) ligand (CXCL)9, CXCL10, macrophage inﬂammatory
rotein (MIP)-1, MIP-1 and Rantes, factors enhancing lympho-
yte recruitment. It has been recently suggested that in vitro MSC
xpansion media can affect this phenotype, with platelet lysate
upplemented media favoring a pro-inﬂammatory MSC  phenotype
nd secretion of granulocyte macrophage–colony stimulating fac-
or (GM-CSF), which may  enhance immune cell recruitment and
aintenance of macrophages in an M1 phenotype (Fig. 1) [14].
In their unlicensed state, MSC  exhibit immune homeostatic
unctions. This is enhanced by exposure of the cells to pro-
nﬂammatory cytokines such as IFN and TNF and/or TLR3 ligands
uch as dsRNA, as evidenced by increased production of immuno-
uppressive cytokines such as indoleamine 2,3-dioxygenase (IDO)
nd prostaglandin E2 (PGE2; Fig. 2) [2,12]. This inﬂammatory
icensing is likely to be akin to that after MSC  infusion into patientsy Letters 168 (2015) 140–146 141
with systemic inﬂammation, such as sepsis. In vivo murine models
of sepsis and sepsis-associated kidney injury support this theory,
reporting a decrease in inﬂammation and improved tubular recov-
ery with infusion of MSCs [2,15,16].
1.3. Neutrophils
Neutrophils are the most prevalent innate immune cell,
responding to microbial challenge by accumulating at the wound
site within minutes of injury. These non-proliferative, phago-
cytic cells respond to microbial challenge by releasing bactericidal
molecules, reactive oxygen species and producing neutrophil extra-
cellular traps, webs of chromatin derived from the neutrophil
nucleus containing proteases [17].
It has been demonstrated within mice that tissue resident MSCs
are central to the recruitment of neutrophils, exhibiting a pro-
inﬂammatory phenotype and secreting chemotactic cytokines such
as IL-6, IL-8, GM-CSF and macrophage inhibitory factor (MIF; Fig. 1)
[8]. IL-8 is a major chemoattractant for neutrophils, regulating
CD11b expression and thereby mediating leukocyte extravasation
[18]. These ﬁndings are further evidenced by results from a murine
sepsis model where infusion of MSCs was  shown to aid bacterial
clearance through enhancing neutrophil phagocytic activity [19].
Neutrophils are notoriously short-lived immune cells and their
survival is central to the elimination of infection and in facilitat-
ing tissue repair [20]. BMMSCs, unlicensed and to a greater extend
TLR triggered, act to promote survival of both resting and acti-
vated neutrophils through the secretion of IL-6, IFN and GM-CSF.
This is evidenced by increased expression of the anti-apoptotic fac-
tor MCL1 and down-regulation of the pro-apoptotic molecule BAX
within neutrophils on exposure to MSCs. IL-6 promotion of neu-
trophil survival has been reported to be via the signal transducer
and activator of transcription (STAT)-3 pathway [21,22]. Neu-
trophils are also maintained “healthy” by BMMSC  enhancement of
neutrophil burst activity, which in combination with increased sur-
vival enables maintenance of a neutrophil store for rapid release on
detection of pathogen [8].
1.4. Mast cells
Mast cells (MCs) are the key innate responder cells in allergic
inﬂammation. They reside in tissues close to the external environ-
ment, their location meaning that interactions between BMMSCs
and MCs  are highly probable during MSC  homing. MCs  originate
from hematopoietic stem cells (HSC), circulating within the periph-
eral blood as CD34+ precursors where they migrate into the tissue
and mature into effector cells. Shortly after allergen exposure the
BM releases CD34+ precursors, which are recruited to the site of
allergen [23]. Both these precursor and mature MCs  play a central
role in inducing allergic inﬂammation by producing high levels of
Th2 cytokines. Although primarily known for their role in allergy,
MCs  have been shown to play a key role in defense and autoimmu-
nity and therefore are also an important part of many Th2 mediated
inﬂammatory diseases.
MCs  mediate allergic anaphylaxis through the release of his-
tamine during degranulation. Histamine has been demonstrated
to stimulate the secretion of a number of cytokines including IL-
1 and IL-6 in different cell types. BMMSCs have been reported to
express the necessary receptors H1, H2 and H4 to interact with his-
tamine [24]. Histamine and BMMSCs primarily interact via the H1
receptor, inducing IL-6 production within the MSCs in a dose and
time-dependent manner. In addition PGD2, a MC  lipid mediator,
further stimulates IL-6 secretion by BMMSCs. These enhanced lev-
els of IL-6 secretion aid in the prevention of pro-apoptotic activity
on neutrophils whilst increasing superoxide production within the
phagocytic cells [24].
142 K. Le Blanc, L.C. Davies / Immunology Letters 168 (2015) 140–146
Fig. 1. Targeted actions of the pro-inﬂammatory MSC. MSCs challenged with Gram positive (peptidoglycan; PGN) and Gram negative (lipopolysaccharide; LPS) bacteria skew
to  a pro-inﬂammatory phenotype. MSC  secretion of IL-6, IL-8, IFN, MIF and GM-CSF increases neutrophil migration to the site of infection/injury, enhancing their activation
and  phagocytosis whilst promoting their survival. Pro-inﬂammatory MSC  secretion of CCL2, CCL3 and CCL12 recruits monocytes to the site of injury where they differentiate
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MSCs can suppress allergic responses and chronic inﬂamma-
ion in experimental models of asthma [25] and allergic rhinitis
26]. IgE mediated MC  degranulation, resulting in the release of
ro-inﬂammatory mediators, promotes the recruitment of neu-
rophils and dendritic cells (DCs) by enhancing T-cell activation
nd regulating the cytokine microenvironment. MSCs can effec-
ively suppress MC  activation both in vitro and in vivo, in addition
o reducing FcRI-mediated degranulation, TNF production and
tem cell factor induced migration [27–29]. In vitro this inhibitory
ffect can be reversed by inhibiting the production of PGE2 and
ransforming growth factor 1 (TGF1; Fig. 2) [28,29]. The effect of
he MSC  secretome on MC  function has further been demonstrated
n a model of experimental allergic conjunctivitis (EAC) [30]. Within
his model, MSC  conditioned media effectively reduced IgE produc-
ion, histamine release and activation of MCs  during the effector
hase of EAC; working speciﬁcally through the NF-B pathway via
yclooxygenase (COX) 2 [30]. When in direct contact with MCs,
MMSCs are able to suppress degranulation, pro-inﬂammatory
ytokine production, chemotaxis and chemokinesis. These effects
re dependent on cross-talk between the cells, the up-regulation
f COX2 within BMMSCs and the binding of secreted PGE2 to the
P4 receptor on MCs  [27].
.5. Natural killer cells
Natural killer (NK) cells have a surveillance role in eliminating
oth virally infected and stressed cells. These cells are of partic-
lar interest in understanding mechanisms of rejection and are
entral to the regulation of cytotoxicity in response to human
eukocyte antigen (HLA) molecules. NK cells comprise the primaryin the macrophages in the M1  phenotype enhancing bacterial clearance and early
lymphocyte population after HSC transplantation (HSCT) and medi-
ate a signiﬁcant Graft versus Leukemia effect [31,32]. With an
increasing trend in the use of MSCs in the treatment of Graft versus
Host Disease (GvHD), it is crucial to understand the interactions
and effects of MSCs and NK cells.
NK function is regulated by expression of both activating and
inhibitory receptors, with activation controlled by balance of pro-
and inhibitory signals [33]. NK cells are activated by exposure to IL-
2 or IL-15, resulting in the secretion of IFN and TNF, which both
play pivotal roles in the subsequent adaptive immune response.
NK cells target cells which have down-regulated HLA I expression,
a characteristic of tumor and virally infected cells, as recognized by
the inhibitory receptors NKG2A and Killer Ig-like Receptors (KIRs),
and resulting in cytolysis by perforins, granzyme and Fas ligand [8].
BMMSCs directly interfere with the proliferation, cytokine pro-
duction and in some cases cytotoxicity of NK cells. MSC-NK
interactions are complex and largely dependent on the microen-
vironment and activation status of the NK cells. BMMSCs suppress
IL-2 and IL-15 induced proliferation and IFN production, but not
the cytotoxicity of freshly isolated NK cells [34,35]. In contrast,
when confronted with previously activated NK cells, MSCs can
interfere with NK mediated cytotoxicity, cytokine production, the
expression of activating receptors on the cells surface of the NK cells
(including NKp30, NKp44 and NKG2D) and granzyme B release. This
is primarily mediated by cell–cell contact and the secretion of IDO,
PGE2, TGF1, HLA-G5 and activin-A (Fig. 2) [8,35,36].HLA mismatched MSCs are not immune to NK mediated cyto-
toxicity. Human BMMSCs express a number of ligands capable of
activating NK cell receptors, such as ULBP-3 as well as nectin-2,
CD54 and CD155. These MSCs are susceptible to lysis by IL-2 and/or
K. Le Blanc, L.C. Davies / Immunology Letters 168 (2015) 140–146 143
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gig. 2. The multi-faceted anti-inﬂammatory actions of MSCs. In response to pro-in
hrough the secretion of soluble factors these licensed cells can act on numerous in
iscussed further within the main text.
L-15 activated or IL-12 and/or IL-18 activated NK cells, but not
esting NK cells [8,34,37,38]. Licensed MSCs exposed to IFN are
rotected from NK mediated cell killing, potentially due to their
p-regulated cell surface expression of HLA I (an inhibitory signal
o the NK cells) and down-regulation of ULBP-3 (an activating sig-
al), which alongside an increased production of both IDO and PGE2
ffers multiple mechanisms for dampening NK responsiveness to
he MSCs [8].
.6. Dendritic cells
DCs provide a link between the innate and adaptive immune
ystems, presenting antigen to T-cells and regulating their activa-
ion, in addition to directly interacting with B [39] and NK cells [40].
Cs can be immune-inducing and tolerogenic, dependent on their
aturation state and the speciﬁc DC subset. Immature DCs (iDCs),
xhibit a tolerogenic phenotype, expressing low levels of HLA II and
o co-stimulatory molecules. Like their mature (mDC) counterpart,
DCs possess the ability to recognize, process and present antigen to
-cells. In the absence of co-stimulatory molecules however, T-cell
nergy or apoptosis is induced as apposed to activation.
MSCs can directly inhibit both the maturation of monocytes
nd CD34+ precursor cells into DCs and the direct activation of
Cs via the secretion of PGE2, IL-6, tumor necrosis factor-inducible
ene 6 (TSG-6), M-CSF and Jagged-2 mediated signaling (Fig. 2)
29,41–44]. The expression of cell surface receptors associated with
C maturation is reduced in response to MSC  exposure, including
LA II, CD80 and CD86 [45]. A further shift in the DC secre-
ome from pro-inﬂammatory cytokines such as TNF and IL-12,
o anti-inﬂammatory IL-10 suggests the induction of a tolero-
enic phenotype, with downstream adaptive skewing to a Th2 andatory cytokines or TLR3 stimuli, MSCs will develop an anti-inﬂammatory proﬁle.
mmune cells affecting both effector function and phenotype. Individual effects are
Treg response [46]. IL-6 mediated inhibition of DC maturation and
tolerogenic skewing has been linked to the up-regulation of SOCS1,
a central regulator of the immune system and preventer of systemic
autoimmunity [47,48].
Taken together, iDCs through their exposure to MSCs are unable
to effectively induce the activation of T-cells, with a reduced capac-
ity to present antigen and stimulate T-cell proliferation and naïve
T-cell differentiation, suggesting an indirect mechanism of MSC-
mediated immunosuppression [45,46]. MSCs can also act directly
on mDCs, reverting them to a renewed immature phenotype asso-
ciated with a down-regulation of their cell surface expression of
antigen-presenting and co-stimulatory molecules, IL-12 secretion
and an inability to stimulate lymphocyte proliferation in vitro [49].
1.7. Myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) comprise a het-
erogeneous population of myeloid precursors of macrophages,
granulocytes and DCs. Exploiting their immunosuppressive nature,
MDSCs have been implicated in autoimmune diseases including
type 1 diabetes [50] as well as in maintaining chronic inﬂammation
[51].
Within mice, MDSCs have been demonstrated to suppress cyto-
toxic T-cell effector function through the up-regulation of Arginase
1 and nitric oxide synthase 2 [52]. Limited work has been under-
taken to investigate the link between MSCs and MDSCs, although
MSC  derived soluble factors play a signiﬁcant role in their inter-
action. MSCs secrete CXCL3, a member of the growth-related
oncogenes (GRO-), directly inhibiting the differentiation and func-
tion of MDDCs, promoting their skewing to a MDSC phenotype
both in vitro and in vivo (Fig. 2) [53]. This is accompanied by an
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p-regulation of the MDSC related genes, COX2, IDO, programmed
eath ligand (PD-L) 1 and 2 and matrix metalloproteinase 9 (MMP9)
n human MDDCs. MSC  secreted hepatocyte growth factor (HGF)
an further support the expansion of these cells by directly bind-
ng the HGF receptor, c-met and increasing STAT3 phosphorylation
tatus within the MDSCs (Fig. 2) [54]. IL-6, a cytokine constitu-
ively secreted by MSCs has also been demonstrated to support
his expansion process [55].
.8. Monocytes
Monocytes represent approximately 10% of circulating leuko-
ytes within humans [56]. Derived from myeloid precursors, this
opulation of cells represents the precursors for macrophages and
Cs. Human monocytes are heterogeneous and can be divided into
t least 3 subsets based on their expression of CD14 and CD16;
he classical monocytes (CD14++CD16−)  and the minor subsets
f CD16+ monocytes (CD14++CD16+ and the pro-inﬂammatory
D14+CD16+)[57].
Murine and human BMMSCs promote the movement of mono-
ytes out of the BM space after detecting microbial pathogens
nd enhance the recruitment of monocytes and macrophages into
nﬂamed tissues to promote wound repair through the secre-
ion of the chemokine (C-C motif) ligands CCL2, CCL3 and CCL12
Fig. 1)[58]. In addition to their effects on monocyte progeny, MSCs
irectly act on CD14+ monocytes through the secretion of HGF and
otentially factors downstream of the COX2 pathway [45,59]. HGF
s known to modulate T-cell function, however in order to exert
hese effects monocytes expressing c-met are required. Splenic,
ut not BM or peripheral blood derived CD14+ monocytes respond
o MSC  secreted HGF by inducing an immunomodulatory pheno-
ype, and are able to rapidly expand within the circulation before
ecoming an adherent macrophage (Fig. 2) [59].
.9. Macrophages
Macrophages are characterized into two phenotypes, the M1
ro-inﬂammatory macrophage with antimicrobial activity and the
2 anti-inﬂammatory macrophage. These categories relate pri-
arily to their differential secretion of cytokines and expression
f cell surface markers. The interactions between macrophages
nd BMMSCs have been demonstrated within the BM,  working
n symbiosis for stem cell homeostatic maintenance and potential
icrobial challenge.
Monocytes entering the inﬂammatory environment will
espond to local chemical signals, differentiating into either M1
acrophages secreting IFN and TNF to support and enhance
nﬂammation, or M2  macrophages promoting transition to the
eparative stage of wound healing by secreting anti-inﬂammatory
actors such as IL-10 and TGF1.
MSC  educated macrophages demonstrate increased migratory
nd proliferative capacity [60]. Recent studies have reported the
bility of MSCs to modulate the phenotype of macrophages by
nducing a shift from M1  to M2,  thereby accelerating the wound
ealing process [12,61]. Co-cultures of human BMMSCs with
acrophages induce expression of CD206 and CD163 and a down-
egulation of the co-stimulatory molecule CD86, suggesting an M2
henotype. This is accompanied by high-level secretion of IL-10
nd IL-6, low levels of IL-12 and TNF and a functionally higher
hagocytic activity [8]. The secretion of IL-10 by both monocytes
nd M2  polarized macrophages can prevent neutrophils migrating
nto the inﬂamed tissue and thereby reduce oxidative damage, indi-
ectly aiding bacterial clearance due to a resulting higher number of
eutrophils within the blood [19]. This illustrates the role of MSCs
n orchestrating the inﬂammatory response, enhancing neutrophil
igration into the inﬂamed environment during the early phases toy Letters 168 (2015) 140–146
promote an innate immune response and switching to a inhibitory,
inﬂammation dampening role later to prevent prolonged damage
to the tissue.
The role of MSCs in post-injury inﬂammation has also been
documented within the brain [62]. Microglia (brain resident
macrophages) were reported to polarize to an M2  phenotype in
mice with brain injuries injected intracerebroventricularly with
human MSCs. This effect was  accompanied by a reduction in phago-
cytosis, early recovery of neurological functions and reparative
changes within the lesion site, suggesting a role in both growth
stimulation and tissue repair [62].
MSCs have also been reported to directly induce an M2  phe-
notype from monocytes. This directed maturation is partially
regulated via direct cell contact but also by BMMSC secretion
of PGE2, IL-6 and IDO (Fig. 2) [63–65]. Secretion of PGE2 by
MSCs simultaneously stimulates the proliferation of epithelial cells
and therefore it has been hypothesized that the MSC  role as an
immunomodulator and healing promoting cell may be linked [8].
Changes in concentrations of these soluble signaling molecules may
aid in the regulation and balancing of both the shift from M1  to M2
and the transition of pro- to anti-inﬂammatory MSCs.
A strong link between polarization of macrophages by MSCs
and modulation of T-cell behavior has been demonstrated. Pro-
inﬂammatory cytokine release by activated T-cells, including IFN
and TNF increases the expression of COX2 and IDO in MSCs, fur-
ther enhancing macrophage polarization [12]. M2  polarization of
macrophages has also been associated with the induction of Tregs
and therefore linking to the adaptive immune response [63]. Inter-
estingly, it has been demonstrated that removal of monocytes from
PBMC:MSC co-cultures reduces suppressive effects [63,66]. The rel-
evance of these ﬁndings linking MSCs to macrophage polarity has
been supported by in vivo investigations. In a mouse model of sep-
sis, infusion of murine BMMSCs only decreased lethality in the
presence of active macrophages, with depletion of macrophages
or the presence of IL-10 neutralizing antibodies preventing this
response [8].
Summary
MSCs have been trialed extensively for their immunomodula-
tory and trophic properties within the clinic, earning these cells
the term “injury drugstore” [67]. With increasing evidence for
the role of MSCs in direct modulation of the innate immune sys-
tem, MSC  therapy is increasingly being viewed as a novel and
promising treatment for diseases such as bacterial pneumonia [68],
sepsis [65] and acute lung injury [69]. It is clear, that although
the speciﬁc mechanisms of action by which MSCs exert their
immunomodulatory effects in vivo remain largely unknown, these
therapeutic cells are highly regulated by their microenvironment
and paracrine signals. Within this review we  have discussed the
mechanisms of action by which MSCs exert key effects on differ-
ent innate immune cell subsets, demonstrating the importance of
both cellular interactions and the MSC  secretome. Further under-
standing of these interactions will be crucial in improving and
developing new clinical protocols for MSC  based cell therapy in
the future.
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